NRx Pharmaceuticals, Inc.
NRXP
$3.28
$0.072.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -28.62M | -38.06M | -33.79M | -24.11M | -25.13M |
| Total Depreciation and Amortization | 143.00K | 44.00K | 3.00K | 4.00K | 5.00K |
| Total Amortization of Deferred Charges | 350.00K | 725.00K | 1.25M | 1.25M | 896.00K |
| Total Other Non-Cash Items | 12.61M | 24.83M | 21.19M | 9.41M | 8.30M |
| Change in Net Operating Assets | 1.41M | -35.00K | -559.00K | 3.00M | 5.29M |
| Cash from Operations | -14.11M | -12.50M | -11.91M | -10.45M | -10.64M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -2.38M | -2.56M | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -432.00K | -- | -- | -- | -- |
| Cash from Investing | -2.81M | -2.56M | -- | -- | -- |
| Total Debt Issued | 5.23M | 9.37M | 12.53M | 12.08M | 7.08M |
| Total Debt Repaid | -548.00K | -4.17M | -6.81M | -6.74M | -8.58M |
| Issuance of Common Stock | 9.47M | 9.47M | 3.47M | 6.62M | 5.91M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 9.13M | 5.93M | 3.73M | 2.72M | 3.07M |
| Cash from Financing | 23.28M | 20.60M | 12.92M | 14.68M | 7.49M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.35M | 5.54M | 1.01M | 4.23M | -3.15M |